Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Zynerba Pharmaceuticals Inc (ZYNE)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Zynerba Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Zynerba Pharma historical data, for real-time data please try another search
1.300 +0.000    +0.00%
10/10 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.260 - 1.340
Zynerba Pharma 1.300 +0.000 +0.00%

Zynerba Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Zynerba Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

26

Equity Type

ORD

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.

Contact Information

Address 80 West Lancaster Avenue Suite 300
Devon, 19333
United States
Phone 484 581 7505
Fax -
Web www.zynerba.com
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ZYNE Comments

Write your thoughts about Zynerba Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Csaba Kiss
Csaba Kiss Oct 12, 2023 2:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I'm not happy with the sale, it would have been better if the company continued the introduction and got off the ship after a successful FDA decision, then the $8 would have been fine, there is nothing to do but say goodbye to the comrades, good luck to everyone in other pharmaceuticals.
Reply
0 0
Report
Ramba Łej
Kubizm Oct 11, 2023 10:25AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bye bye Zyne.
Reply
0 0
Report
Csaba Kiss
Csaba Kiss Sep 16, 2023 10:04AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
On the day of the buyout offer, it was deposited at 1.37, it did not go away, I withdrew it the next day, there is no point in charting, here the news is measured at 300%, so the stop is not, either to give, or upon agreement when selling the patent protection, or the introduction request upon submission to the FDA. Zero still has a 10-20% chance, the rest shares the band between $2.5 and $10, for a company with 25 employees, if you manage to sell the license, the revenue will reach $1 billion around 2027-28, the royalty would be 20% , this story would not move anything at Pfizer, there are 83,000 employees. We have to wait for the sale of the Zygel distribution, in the form when the royalty payment is made every 1/4th year for 18 years, then we would see a day of +300% again, these $60 and +140 m promise little. Don't worry, don't watch the news, patience everyone!
Reply
0 0
Report
Ramba Łej
Kubizm Sep 11, 2023 4:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I found 3 lawfirms that are investigating potential Board's lack of diligence regarding Harmony deal since there are lots of milestones to achive for ZYGEL to get 140 mln additional price for shareholders. Acording to one of the annoucments there are certain guarantees for board members for theirs paychecks while extra payment for shareholders are gloomy regarding strict conditions for ZYGEL
Reply
0 0
Report
Csaba Kiss
Csaba Kiss Sep 11, 2023 4:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Slow down, Amigo, if they don't sell it, but sell it directly after the launch, then not $140m once, but even $200m royalties per year after traffic starts up for 15 years, when the protection expires, which is 18 years anyway, you're a beginner you are a competitor in this pharmaceutical profession, I will not take you on as a student-:)XD
Reply
0 0
Report
Ramba Łej
Kubizm Sep 11, 2023 4:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Csaba Kiss just sayin if some is interested :)
Reply
0 0
Report
Csaba Kiss
Csaba Kiss Sep 06, 2023 2:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I hold it firmly, I have no intention of selling it, the next +300% day would be the submission of the FDA registration application, do the math, I assume a royalty transfer of $3/share for the sale of the distribution, 25 employees will not live up to it, a fabulous dividend would come, the current exchange rate double, there is still the possibility of a fall, but the chance of this has greatly decreased. Patience everyone, it's a patience game now.
Reply
0 0
Report
Csaba Kiss
Csaba Kiss Aug 14, 2023 11:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Írja I looked at ZYNERBA as either zeroing out, maybe 10x, it is working on the launch of an ointment containing cannabis, in relation to rare mental illnesses, the launch was promised next year, I considered it possible to reach even $1 billion in revenue, if it were to sell, then 3 years after the launch after peaking, $200 million/year in royalties would arrive. Today, the hard rock hit, a buyout offer of $1.1059 in cash + $140 million in milestones upon successful launch, Cash/share 84 cents, it also traded at an abnormal 30 cents, 1/3 of the stock, so the buyer would only pay 26 cents including kp, working capital covers short-term liabilities 5x, it can last until the introduction, if it comes together at the FDA, then + 140 is in play, which is 3x even from here, exchange rate +277% now, but the real big money, 3x would also multiply , if they don't give it and sit in the gold mine. I've always loved and felt for pharmaceuticals, until now Cariprazine launch in September 2015, Allergan buyout, BIOGEN Alzheimer's story, this would be the icing on the cake.meg véleményét a Zynerba Pharmaceuticals Inc.-ről
Reply
0 0
Report
Ramba Łej
Kubizm Aug 10, 2023 9:14AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
haha ZYNE can't push reverse stock split because of the absence of shareholders on meetings xD Zyne became garbage stock
Reply
2 0
Report
Csaba Kiss
Csaba Kiss Aug 10, 2023 9:14AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
-:)XDDDDDDDDDD
Reply
1 0
Report
Ramba Łej
Kubizm May 17, 2023 10:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zynerba intends to seek approval of a reverse stock split at its Annual Meeting of Stockholders in June (Annual Meeting), which it would effect any time prior to November 1, 2023. Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting. The primary objective of implementing a reverse split is to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Company’s Board believes that effecting the reverse split would increase the price of our common stock which would, among other things, help the Company to: Meet certain continued listing requirements of the Nasdaq Capital Market; Appeal to a broader range of investors to generate interest in the Company; and Improve perception of the Company’s common stock as an investment security.
Reply
0 0
Report
Ramba Łej
Kubizm May 17, 2023 10:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
long story short, zyne performes so "good" that would be delisted
Reply
0 0
Report
Ramba Łej
Kubizm May 16, 2023 7:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
and now money burs faster and faster bye bye zyne
Reply
0 0
Report
Равиль Зайнуллин
Равиль Зайнуллин Mar 13, 2023 8:03AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
🤮🤮🤮🤮
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email